Technology | August 29, 2006

Nuclear Stress Test Combines Assessment of Perfusion, Function

Offering a combination of perfusion and function information in a single nuclear stress test, Lantheus Medical Imaging's Cardiolite kit for the preparation of technetium Tc99m sestamibi for injection enables physicians to assess patient risk and optimize patient management.
Because perfusion is a strong predictor of myocardial infarction and cardiac death, doctors imaging with Cardiolite can evaluate the extent of disease, measure severity of perfusion defects and determine reversibility of defects. Testing myocardial function with Cardiolite means physicians can determine left ventricular ejection fraction and regional left ventricular function as well as wall motion and wall thickening. Cardiolite provides insights for specific patient populations with known or suspected CAD who may present with atypical symptoms.

Related Content

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
Overlay Init